Tenecteplase biosimilar - Reliance Life Sciences

Drug Profile

Tenecteplase biosimilar - Reliance Life Sciences

Alternative Names: R-TPR-012

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reliance Life Sciences
  • Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myocardial infarction

Most Recent Events

  • 26 Sep 2016 Preclinical trials in Myocardial infarction in India (IV)
  • 26 Sep 2016 Reliance Life Sciences plans a phase III trial for Myocardial infarction in India (Reliance Life Sciences)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top